• Capricor outlined Phase 3 HOPE-3 data for deramiocel in Duchenne muscular dystrophy, citing a statistically significant PUL 2.0 total score benefit.
• Primary endpoint showed a 4.55% treatment difference on percent change, p=0.029 (MMRM); sensitivity analysis on absolute change was 1.1, p=0.05.
• Cardiomyopathy subgroup with evaluable MRI LVEF (n=64) showed a 2.9% LVEF difference, p=0.035 (ranked ANCOVA); p=0.026 (Wilcoxon).
• Materials highlighted protocol and statistical analysis plan revisions tied to FDA feedback; SAP 3.0 was finalized before database lock and unblinding.
• Program summary cited more than 200 DMD patients across trials, with generally favorable tolerability and no serious safety issues highlighted in earlier studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.